BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 2877575)

  • 1. Famotidine in the therapy of gastric hypersecretory states.
    Vinayek R; Howard JM; Maton PN; Wank SA; Slaff JI; Gardner JD; Jensen RT
    Am J Med; 1986 Oct; 81(4B):49-59. PubMed ID: 2877575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome.
    Howard JM; Chremos AN; Collen MJ; McArthur KE; Cherner JA; Maton PN; Ciarleglio CA; Cornelius MJ; Gardner JD; Jensen RT
    Gastroenterology; 1985 Apr; 88(4):1026-33. PubMed ID: 2857672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Famotidine: effective treatment of Zollinger-Ellison syndrome.
    Howard JM; Vinayek R; Maton PN; Wank SA; Gardner JD; Jensen RT
    J Clin Gastroenterol; 1987; 9 Suppl 2():23-5. PubMed ID: 2887615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effectiveness of ranitidine and cimetidine in inhibiting acid secretion in patients with gastric hypersecretory states.
    Jensen RT; Collen MJ; McArthur KE; Howard JM; Maton PN; Cherner JA; Gardner JD
    Am J Med; 1984 Nov; 77(5B):90-105. PubMed ID: 6150641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parenteral control of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Vinayek R; Hahne WF; Euler AR; Norton JA; Jensen RT
    Dig Dis Sci; 1993 Oct; 38(10):1857-65. PubMed ID: 8104773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of ranitidine and cimetidine in the treatment of gastric hypersecretion.
    Collen MJ; Howard JM; McArthur KE; Raufman JP; Cornelius MJ; Ciarleglio CA; Gardner JD; Jensen RT
    Ann Intern Med; 1984 Jan; 100(1):52-8. PubMed ID: 6318628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome.
    Campoli-Richards DM; Clissold SP
    Drugs; 1986 Sep; 32(3):197-221. PubMed ID: 2875864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in the management of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Maton PN; Gardner JD; Jensen RT
    Gastroenterol Clin North Am; 1989 Dec; 18(4):847-63. PubMed ID: 2575602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of famotidine with cimetidine and ranitidine.
    Berardi RR; Tankanow RM; Nostrant TT
    Clin Pharm; 1988 Apr; 7(4):271-84. PubMed ID: 2896559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Famotidine. The ACG Committee on FDA-Related Matters with primary authorship by G. Friedman. American College of Gastroenterology.
    Am J Gastroenterol; 1987 Jun; 82(6):504-6. PubMed ID: 2883885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of acid suppressants in patients with Zollinger-Ellison syndrome.
    Maton PN
    Aliment Pharmacol Ther; 1991; 5 Suppl 1():25-35. PubMed ID: 1679671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parenteral antisecretory drug therapy in patients with Zollinger-Ellison syndrome.
    Saeed ZA; Norton JA; Frank WO; Young MD; Maton PN; Gardner JD; Jensen RT
    Gastroenterology; 1989 Jun; 96(6):1393-402. PubMed ID: 2565842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.
    Langtry HD; Grant SM; Goa KL
    Drugs; 1989 Oct; 38(4):551-90. PubMed ID: 2573505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [24-hour intragastric acid profile in a ZES patient with H2 blockers].
    Dammann HG; Müller P; Simon B; Kommerell B
    Z Gastroenterol; 1984 Jun; 22(6):318-20. PubMed ID: 6147052
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacology and clinical efficacy of ranitidine, a new H2-receptor antagonist.
    Helman CA; Tim LO
    Pharmacotherapy; 1983; 3(4):185-92. PubMed ID: 6136952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Famotidine in the treatment of gastric and duodenal ulceration: overview of clinical experience.
    Bianchi Porro G
    Digestion; 1985; 32 Suppl 1():62-9. PubMed ID: 2866137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double blind comparison of the effects of cimetidine, ranitidine, famotidine, and placebo on intragastric acidity in 30 normal volunteers.
    Merki HS; Witzel L; Walt RP; Neumann J; Scheurle E; Mappes A; Krammisch H; Heim J; Kaufmann D; Roehmel J
    Gut; 1988 Jan; 29(1):81-4. PubMed ID: 2893761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of omeprazole in seven patients with Zollinger-Ellison syndrome resistant to histamine H2-receptor antagonists.
    Delchier JC; Soule JC; Mignon M; Goldfain D; Cortot A; Travers B; Isal JP; Bader JP
    Dig Dis Sci; 1986 Jul; 31(7):693-9. PubMed ID: 2873001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of 800 mg cimetidine once daily on gastric acid secretion.
    Dammann HG; Walter TA; Mueller P; Simon B
    Scand J Gastroenterol Suppl; 1986; 121():25-9. PubMed ID: 3532295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety.
    Metz DC; Strader DB; Orbuch M; Koviack PD; Feigenbaum KM; Jensen RT
    Aliment Pharmacol Ther; 1993 Dec; 7(6):597-610. PubMed ID: 8161665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.